Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Featured Story

mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market

By Angus Liu

Compared with Moderna and the Pfizer-BioNTech partnership, which already have their COVID-19 vaccines authorized for emergency use, CureVac seems a little late to the mRNA race. But now, Bayer has signed on to help accelerate development, boost manufacturing—and prep for a possible launch.

When will primary care docs get the COVID-19 vaccine? Many still in the dark

By Heather Landi

While front-line hospital workers across the country began receiving the COVID-19 vaccine last month, many primary care doctors have no direct link to the vaccine rollout and are left in the dark about their turn in line.

Look out, pharma. A 'tidal wave' of side effect reports is coming amid COVID-19 vaccine rollouts

By Eric Sagonowsky

With COVID-19 vaccine launches gaining steam—and an unprecedented level of media coverage zeroed in—pharma companies of all stripes should brace for a wave of side effect reports, experts say. And it won't just intensify adverse-event tracking, but the threat of lawsuits, too.

AHA presses for changes to COVID-19 vaccine rollout and for HHS to take larger role

By Robert King

AHA gave HHS some recommendations to improve the rollout of the COVID-19 vaccine after some hospitals have complained of disparate plans between states.

Here's the latest CDC update clinicians should know when it comes to COVID-19 vaccine reactions

By Tina Reed

Docs are fielding plenty of questions about the COVID-19 vaccine right now. Here's a look at the latest data from the Centers for Disease Control and Prevention.

Healthcare roundup: HHS extends community-based COVID-19 testing sites

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: Sanofi's Kevzara, Roche's Actemra curb death rates in U.K. trial

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

Big Pharma Bayer is helping CureVac on its mRNA vaccine. Arthritis drugs from Roche and Sanofi helped the sickest patients in a U.K.-funded COVID-19 trial. Aspen could start producing J&J doses in March or April. Peru inked vaccine orders with Sinopharm and AstraZeneca. Plus, Sinovac's shot proved 78% effective in phase 3.

In Los Angeles and beyond, oxygen is the latest COVID-19 bottleneck

By Lauren Weber,Rae Ellen Bichell, Kaiser Health News

As Los Angeles hospitals give record numbers of covid patients oxygen, the systems and equipment needed to deliver the life-sustaining gas are faltering.

BioNTech CEO applies COVID-19 vaccine's mRNA tech to multiple sclerosis